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Abstract
Background: Rotavirus is the most common cause of severe gastroenteritis among young children in Spain and
worldwide. We evaluated hospitalizations due to community and hospital-acquired rotavirus gastroenteritis (RVGE)
and estimated related costs in children under 5 years old in Catalonia, Spain.
Results: We analyzed hospital discharge data from the Catalan Health Services regarding hospital admissions
coded as infectious gastroenteritis in children under 5 for the period 2003-2008. In order to estimate admission
incidence, we used population estimates for each study year published by the Statistic Institut of Catalonia
(Idescat). The costs associated with hospital admissions due to rotavirus diarrhea were estimated for the same
years. A decision tree model was used to estimate the threshold cost of rotavirus vaccine to achieve cost savings
from the healthcare system perspective in Catalonia. From 2003 through 2008, 10655 children under 5 years old
were admitted with infectious gastroenteritis (IGE). Twenty-two percent of these admissions were coded as RVGE,
yielding an estimated average annual incidence of 104 RVGE hospitalizations per 100000 children in Catalonia.
Eighty seven percent of admissions for RVGE occurred during December through March. The mean hospital stay
was 3.7 days, 0.6 days longer than for other IGE. An additional 892 cases of presumed nosocomial RVGE were
detected, yielding an incidence of 2.5 cases per 1000 child admissions. Total rotavirus hospitalization costs due to
community acquired RVGE for the years 2003 and 2008 were 431,593 and 809,224 €, respectively. According to the
estimated incidence and hospitalization costs, immunization would result in health system cost savings if the cost
of the vaccine was 1.93 € or less. At a vaccine cost of 187 € the incremental cost per hospitalization prevented is
195,388 € (CI 95% 159,300; 238,400).
Conclusions: The burden of hospitalizations attributable to rotavirus appeared to be lower in Catalonia than in
other regions of Spain and Europe. The relatively low incidence of hospitalization due to rotavirus makes rotavirus
vaccination less cost-effective in Catalonia than in other areas with higher rotavirus disease burden.
Background
Rotavirus gastroenteritis (RVGE) is the most common
cause of severe gastroenteritis among children under 5
years of age, causing considerable morbidity and mortality
worldwide [1,2]. In Europe, RVGE causes approximately
230 deaths, more than 87,000 hospitalizations and 700,000
outpatient visits annually, consuming substantial health
resources [3]. Although costs for treatment of severe cases
(i.e. those admitted to hospital) are relevant in Europe [4],
rotavirus vaccine is still too expensive to encourage the
implementation of a generalized immunization strategy in
areas of low incidence [5].
Previous studies regarding the burden of rotavirus dis-
ease in Europe and in different autonomous regions
within Spain have yielded varying estimates of the num-
ber of hospitalizations attributable to rotavirus [6-10].
Few studies in Spain have assessed the burden of nosoco-
mial rotavirus infection, even though it is considered to
be one of the principal hospital-acquired infections in
young children [9,11-13]. We describe here the charac-
teristics of hospitalizations associated with rotavirus
infection in the autonomous region of Catalonia during
the years 2003-2008. In addition, we evaluated the cost-
effectiveness and threshold vaccine cost for savings with
rotavirus vaccination.
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Methods
We analyzed hospital discharge data for Catalonia from
the Minimum Basic Data Set for Acute-care Hospitals
(MBDS) of the Catalan Health Services. This data set
comprises data from all public acute care hospitals and
almost 90% of private acute care hospitals.
Diagnoses are coded according to the International Clas-
sification of Diseases, 9th revision, Clinical Modification
(ICD-9-CM). We analyzed data for all hospitalizations of
children less than 5 years of age with a principal diagnosis
of infectious gastroenteritis (IGE) to estimate the fre-
quency of community-acquired RVGE that required hos-
pitalization. We defined community-acquired RVGE as all
hospitalizations with a primary ICD9 CM code for RVGE
(008.61), as well as those with a secondary code for RVGE,
when the primary code was an IGE-related code. To eval-
uate the burden of nosocomial RVGE we selected hospita-
lizations with primary diagnoses that were not related to
IGE but with RVGE coded in any of the secondary diag-
noses. We analyzed data regarding the length of hospital
stay, age, gender, date of admission, and outcome at dis-
charge. The six-year period evaluated started the 1st of
January 2003 and ended the 31st of December 2008.
The following ICD-9-CM codes were selected for IGE:
003.0, 005.0-005.9, 008.0-008.8 and 009.0-009.3. We
excluded codes that are most likely to be imported gastro-
enteritis: cholera (001.0-001.9), typhoid and paratyphoid
fever (002.0-002.9), shigellosis (004.0-004.9) and amoebia-
sis (006.0-006.9), which rarely if ever cause hospitalization
in Catalonia. The primary diagnosis was assumed to be
the main reason for hospital admission. To estimate the
incidence of hospitalizations due to RVGE and other types
of IGE, we obtained population estimates for each study
year published by the Statistic Institut of Catalonia (Ides-
cat). To estimate the incidence of nosocomial hospitaliza-
tions due to RVGE, we obtained the annual number of
hospitalizations of children under 5 years of age from the
annual reports of MBDS. The average length of stay in
hospital was calculated for the different types of IGE and
for each of the study years. Statistical analyses and data
processing were conducted using STATA v.11.0 and Excel
Office 2007.
Total admission costs from the health care perspective
were calculated by multiplying the estimated number of
cases (community acquired RVGE) of each year by the
average rotavirus admission costs. The latter were calcu-
lated using the cost of a proxy Diagnosis Related Group
(DRG) for this disease (see below), which was obtained
from the Spanish Ministry of Health (http://www.msps.es),
and weighted using data from the Centers for Medicare
and Medicaid Service (CMS-DRG version 22) as in López-
de-Andres et al[9]. Since there is no specific DRG for rota-
virus gastroenteritis, DRG 184 (esophagitis, gastroenteritis,
and miscellaneous digestive disorders, age < 18) was used.
Vaccination strategy was compared to “no vaccination”
strategy in a decision tree model using the incidence of
hospitalizations due to community acquired RVGE and
associated costs of one episode estimated in this study.
The tree model calculated the expected values associated
with each strategy, that is, the costs associated with each
strategy weighted by the probability of incurring such
costs. In the model the preferred strategy is the one with
the lower expected cost. Information on vaccine efficacy
was taken from the literature [14] and the current vaccine
price was taken from a publication of the Spanish Ministry
of Health [15]. Conservatively, vaccine price was assumed
to represent all the costs associated with the vaccination
program. Most of the input variables were included as
probability distributions rather than as point estimates to
model uncertainty (Table 1) [16]. Incremental costs per
case prevented were calculated (vaccine cost - costs saved
due to outcomes averted). The decision tree was built
using Tree Age Pro 2008 software (TreeAge Software,
Willamstown, MA).
Ethics
This study did not need to pass ethical approval by an
ethics committee due to the nature of the data (non
experimental). Anonymity was assured as the data pro-
vided by the MBDS of the Catalan Health Services did
not contain any information that would allow identifica-
tion of any subject. The guidelines of the Declaration of
Helsinki on confidentiality and data privacy were
followed.
Results
Community Acquired Rotavirus Gastroenteritis
From 2003 to 2008, 10655 children under 5 years of age
were hospitalized with IGE as a primary diagnosis in
Catalonia (Table 2). These were considered to be com-
munity-acquired IGE. The average age of these children
was 12.3 months (standard deviation (SD) 13.9 months),
and 45% were female.
A total of 2373 hospital admissions had RVGE as either
the primary diagnostic code or had RVGE as a secondary
code with an IGE-related primary code, and were thus
considered community-acquired cases of RVGE. These
hospitalizations with RVGE codes represented 22% of all
IGE hospitalizations. Ninety-eight percent of these hospi-
talizations had RVGE coded as the primary diagnosis. On
average there were 396 community-acquired RVGE hos-
pitalizations per year, varying from 287 in 2003 to 481 in
2005. Using the average population under 5 years of age
during the study period 2003-2008 (380,751 residents)
we estimate that the average annual incidence of RVGE
hospitalization was 104 admissions per 100,000 children
< 5 years, ranging from 84 to 128 in 2003 and 2005
respectively. There were no deaths recorded associated
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with community-acquired RVGE hospitalizations.
Assuming that there are an average of 8 (range 5 to 10)
outpatient visits per hospital admission as Parashar and
colleagues have suggested [2], we estimate that rotavirus
infection causes 3,168 (range 1,980 to 3,960) outpatient
visits annually in Catalonia.
The mean age of children hospitalized for RVGE was
7.6 months (SD 10.1 months), and 42% were female.
Most (54%) RVGE hospitalizations were of children
under 1 year of age and 88% were of children younger
than 2 years. The proportion of IGE attributed to rota-
virus decreased with age (Figure 1).
The seasonality of RVGE admissions and other IGE
admissions is shown in Figure 2. Eighty-seven percent of
RVGE admissions occurred in the months of December
through March, whereas only 46% of admissions for
other IGE occurred during the same months.
The average hospital stay for all children with commu-
nity-acquired IGE was 3.2 days (SD 2.5 days) ranging from
1 to 65 days with a median of 3.0 days (Table 2). Children
with community-acquired RVGE had a slightly longer
average stay than those with other IGE: 3.7 days (SD 2.3)
vs 3.1 days (SD 2.5).
Nosocomial Rotavirus Gastroenteritis
During the period 2003-2008, 892 hospitalizations of
children less than 5 years old had secondary diagnoses of
RVGE with primary diagnoses that were not IGE-related
(Table 3). Hospital-acquired RVGE represented 27%
(892/3,265) of all diagnoses of rotavirus infection. Using
the total number of hospitalizations of children under 5
years of age during the study period (355,339 hospitaliza-
tions) we estimate that the average annual incidence of
presumed nosocomial RVGE was 2.5 cases per 1,000 hos-
pitalizations < 5 years, ranging from 2.0 to 2.8 in 2007
and 2004 respectively. Forty-five percent of the children
with presumed nosocomial RVGE were females; 66%
were less than 1 year of age and 90% were less than 2
years old. The mean age was 5.8 months (SD 9.4), lower
than for community-acquired RVGE.
The mean hospital stay for children with presumed
nosocomial RVGE was 9.7 (SD 13.6) days and the median
was 6 days. Children under one year of age and those 4
years old had longer hospital stays than the rest: mean
stay 10.6 (SD15.1) and 14.0 (SD 12.8) days respectively vs.
7.6 (SD 8.0), 8.3(SD 13.5) and 8.0 days (SD 5.6) for 1, 2
and 3 year-old children respectively. There was one death
associated with presumed nosocomial RVGE in 2006.
Costs and decision tree model
The structure of the decision tree model is depicted in
Figure 3. Costs for 1 episode (admission) range from
431,593€ in the year 2003 to 861,833€ in the year 2006
(table 4). At the current rotavirus vaccine price (187 €-two
doses) the least expensive strategy is “no vaccine”, with an
estimated expected cost of 2.13 € per person compared to
an estimated expected cost of 187.19 € per person asso-
ciated with vaccination. The two strategies become
Table 1 Input parameters for the decision tree model of the comparison of vaccination vs no vaccination strategies in
Catalonia, Spain
Variable Distribution Value Source
Vaccine price* (€) Point estimate 187 Ruiz, J et al. [15]
Vaccine efficacy (%) Uniform Low = 81.8, High = 100 Cortese, MM. et al.[14]
Probability of admission due to disease (%) Triangular Min = 0.084, Best = 0.104, Max = 0.128 Our estimate
Cost of one episode admitted (€) Point estimate 2018.02 DRG estimate for the year 2008
* Price for two doses of the vaccine purchased in Spain in March, 2007
Table 2 Number of infectious gastroenteritis hospitalizations, incidence of hospitalization per 100000 population, and
mean hospital stay among children < 5 years old in Catalonia, Spain, 2003-2008
Gastroenteritis due to Rotavirus Other Infectious Gastroenteritis Total Infectious Gastroenteritis
Year Number Incidence1 Mean stay (SD)2 Number Incidence1 Mean Stay(SD)2 Number Incidence1 Mean Stay(SD)2
2003 287 83.6 3.8 (2.4) 1420 413.7 3.4 (2.5) 1707 497.3 3.5 (2.5)
2004 331 91.8 3.9 (2.3) 1489 412.9 3.3 (3.0) 1820 504.7 3.9 (2.9)
2005 481 127.6 3.6 (1.9) 1332 353.5 3.0 (2.4) 1813 481.1 3.2 (2.3)
2006 472 120.3 3.9 (2.0) 1472 375.1 2.9 (2.4) 1944 495.4 3.2 (2.3)
2007 401 98.5 3.7 (3.0) 1427 350.5 2.9 (2.2) 1828 449.0 3.1 (2.4)
2008 401 99.2 3.5 (2.0) 1142 282.5 2.9 (2.7) 1543 381.7 3.1 (2.6)
Period 2003-2008 2373 103.93 3.7 (2.3) 8282 362.53 3.1 (2.5) 10655 466.43 3.2 (2.5)
1Incidence per 100000 population
2Mean hospital stay in days (standard deviation [SD] in parentheses)
3 Average annual incidence
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equivalent with an expected cost of 2.1 € per person, when
the vaccine cost is reduced to 1.93 €. The incremental cost
per case prevented associated with the vaccination strategy
was estimated to be of 195,388 € (CI 95% 159,300;
238,400).
Discussion
The lack of a specific surveillance system for RVGE
makes it difficult to directly estimate the burden of this
disease in Spain. The percentage of IGE hospital admis-
sions due to rotavirus in Spain ranged from 31% to 45%
in previous studies with similar methodology to ours
[8-10]. We found that 22% of the IGE hospital admis-
sions in children under 5 in Catalonia, from 2003
through 2008, were due to rotavirus infection.
The incidence of admissions for rotavirus during our
study period, 104 per 100,000 children < 5 years, is also
lower than the most recent estimate for the total of Spain
of 135 cases per 100000, and lower than recent estimates
for other European countries [3,7,9,17-19]. Our estimate is
also lower than that from a previous study conducted in
Catalonia (study period 1999-2000) of 125 per 100000
[20]. The lower estimates in Catalonia compared to the
rest of Spain could reflect actual geographic variability in
incidence of rotavirus infection or disease, or could be due
to differences in the sensitivity of the hospital discharge
databases for detecting RVGE. Similarly, the apparent
decreased incidence we found compared to the earlier esti-
mate for Catalonia by Gil et al. might reflect a true
decreased incidence over the years since 2005 or could be
due to changes in detection sensitivity. However, the cov-
erage of MBDS for public hospitals improved from 95% to
100% over the time between the two estimates [20].
The seasonality of RVGE has already been widely
described by many studies in Europe and America, and
Figure 1 Distribution by age of hospital admissions in
Catalonia, Spain, due to rotavirus gastroenteritis (RVGE) and
other infectious gastroenteritis (IGE) among children < 5 years
old, 2003-2008.
Figure 2 Hospitalizations due to rotavirus gastroenteritis (RVGE) and other infectious gastroenteritis (IGE) in children under 5 years of
age in Catalonia, Spain, by year (2003-2008).
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our data also shows increased incidence during winter
months. During the years we evaluated, there was a pro-
gressive increase of incidence through 2005, which is
consistent with results of previous evaluations in Spain
[9]. At least some of the increase could have been due to
enhanced clinical awareness. The slight decrease in hos-
pital admissions in 2007 and 2008 might be attributed to
the introduction of the rotavirus vaccines in the Spanish
market during 2006 and 2007. However, based on num-
bers of vaccine doses sold to pharmacies in Catalonia by
pharmaceutical companies, we estimated vaccine cover-
age among children less than 1 year old at only 20% in
2008. The coverage among children up to 5 years of age
would be much lower, thus limiting the impact of vacci-
nation on hospitalization to date.
We found an average of 0.6 day longer mean hospital
stay for hospitalizations due to RVGE compared with hos-
pitalizations for other causes of IGE. Similar results were
described in other studies using Vesikari’s score to account
for duration and severity of diarrhea [21,22]. Thus we esti-
mate that if there had been vaccination coverage similar to
that for measles, mumps and rubella vaccine (approxi-
mately 96%)[23], and a 90% efficacy of a rotavirus vaccine
[24,25], over 7500 days of hospitalization attributable to
rotavirus could have been prevented over the 6 year study
period. Achieving high vaccine coverage would likely
require inclusion of rotavirus vaccine in the national
immunization program.
The average annual incidence of presumed nosocomial
RVGE in our study period was 2.5 per 1000 hospitaliza-
tions in children < 5 years of age, which is lower than the
incidence of 4.5 per 1000 admissions reported in another
recent study for the whole of Spain [26]. However, in that
study, the incidence for Catalonia of 2.0 cases per 1,000
children under 5 is quite consistent with our estimate and
thus the incidence of nosocomial RVGE in Catalonia
appears to be lower than in the rest of Spain. Our finding
that children under 12 months old appear to be at higher
risk of acquiring nosocomial RVGE than older children, is
consistent with previous studies [26,27].
In the economic evaluation of RVGE, the strategy “no
vaccine” was substantially less expensive than the vaccina-
tion strategy at the current vaccine price of 187 €. At a
vaccine cost of 1.93 € the two strategies had the same
expected cost. A study from the United States estimated
the median cost-effectiveness ratio of vaccination program
per serious case prevented at 3024 US$ [28], substantially
lower than our estimate for Catalonia. Thus, rotavirus
vaccination in Catalonia does not appear to be as cost-
effective as in the United States. The cost-effectiveness
ratio estimated in our study is consistently higher due to
the lower probability of hospitalization, higher vaccine
price and lower costs of hospitalization.
There are limitations to using the MBDS to estimate
RVGE incidence and severity. First, the dataset covers all
public hospitals in our region but it may miss cases of
RVGE that are not laboratory confirmed. Second, a recent
study in Italy indicated that 27% of RV positive cases
admitted to the hospital were not coded as RVGE in the
hospital discharge database, and two studies in Spain
found that 52% (Foster J. et al) and 47% (Gutierrez-
Gimeno et al) of children hospitalized for gastroenteritis
in Spain and prospectively tested for rotavirus infection
were positive [21,29,30]. Similar coding and diagnostic
error in our dataset would result in underestimation of the
true number of RVGE cases. However, the MBDS system
in Catalonia uses an internal and external validation sys-
tem that monitors and updates the hospital discharge data
before processing and storage, thus capturing diagnoses of
cases that were discharged before the results of in-hospital
Table 3 Number of suspected hospital-acquired rotavirus
gastroenteritis, annual incidence, and mean hospital stay
in children < 5 years old in Catalonia, Spain, 2003-2008
Year Number Incidence1 Mean Stay (SD)2
2003 149 2.6 12.1(18.8)
2004 165 2.8 8.1(11.8)
2005 148 2.5 10.6(14.2)
2006 154 2.6 10.1(15.1)
2007 124 2.0 10.3(11.1)
2008 152 2.5 7.2(6.8)
Period 2003-2008 892 2.5 9.7(13.6)
1Incidence per 1000 hospital admissions.
2Mean hospital stay in days (standard deviation [SD] in parentheses)
Figure 3 Decision tree model of the comparison of vaccination vs no vaccination in Catalonia, Spain. *P1 = incidence of RVGE
hospitalization; P2 = Vaccine efficacy.
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microbiological tests. Third, there might be cases of noso-
comial RVGE that are not detected if the symptoms start
after discharge and do not provoke re-hospitalization. On
the other hand, our definition for presumed nosocomial
RVGE might lack specificity if the primary diagnostic code
does not reflect the actual cause of admission and this
would lead to labeling some cases of community-acquired
RVGE as presumed nosocomial RVGE, resulting in an
overestimate of nosocomial RVGE. Fourth, some hospitals
might not run diagnostic tests for RVGE as frequently as
others, yielding an underestimation of RVGE cases. Fifth,
our economic evaluation only concerns community
acquired RVGE and is calculated from the health system
perspective, and therefore does not consider indirect costs
associated with rotavirus admissions (such us travelling
expenses and family members’ days off from work). This
would underestimate the total societal costs of each
admission. However, such indirect costs are likely to be
small compared to the direct costs of hospitalization [30].
Lastly, we have not taken into account the unknown rate
of readmission for RVGE in our study population. Since
the data from MBDS is anonymous, we could not distin-
guish if the same child was hospitalized more than once.
Counting readmissions in our analysis could result in
overestimation of the true incidence of both community
acquired and nosocomial RVGE. However, since primary
rotavirus infection generally protects against subsequent
severe rotavirus illness, we believe that our estimates of
the incidence of hospital-acquired and nosocomial RVGE
are not substantially biased by readmissions.
Conclusions
In conclusion, rotavirus is an important cause of infec-
tious gastroenteritis associated with hospitalization
among children under 5 years old in Catalonia, and espe-
cially among children under 2 years of age. RVGE occurs
mainly in winter months and causes longer hospital stays
than gastroenteritis caused by other infectious agents.
However, the incidence of community acquired and
nosocomial RVGE in Catalonia appears to be lower than
in other regions of Spain and other European countries.
The cost of rotavirus vaccination would need to be sub-
stantially lower than the current cost in order to make
rotavirus vaccination as cost-effective in Catalonia as in
many other areas where universal vaccination has been
implemented.
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